Who is sponsoring NCT01717690?

NCT01717690 is sponsored by Baycrest.

What condition does NCT01717690 study?

NCT01717690 studies Staph Aureus Methicillin Resistant Colonization.

What drugs are being tested in NCT01717690?

Interventions: CHG antiseptic body cleanser.

What is the status of NCT01717690?

NCT01717690 is currently COMPLETED.

Last reviewed 2015-02-20 · How we verify

Randomized Controlled Clinical Trial of 2% Chlorhexidine Gluconate-Impregnated Bath Cloths to Prevent MRSA Colonization on Complex Continuing Care Units of Baycrest Hospital

NCT01717690 Phase 4 COMPLETED

The purpose of this study is to determine whether daily bathing with 2% chlorhexidine gluconate-impregnated antiseptic cleanser (CHG) significantly reduces incidence of colonization of hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA). Investigators postulate that daily bathing with CHG significantly reduces incidence of colonization of hospitalized patients with MRSA.

Details

Lead sponsor	Baycrest
Phase	Phase 4
Status	COMPLETED
Enrolment	122
Start date	2013-08
Completion	2014-09

Conditions

Staph Aureus Methicillin Resistant Colonization

Interventions

CHG antiseptic body cleanser

Primary outcomes

Incidence of MRSA colonization — 12 months
Primary outcome measure will be incidence of MRSA colonization measured through bi-weekly point-prevalence surveys on each of the three units. All new admissions and re-admissions to the units will also be screened. Protective properties of CHG bathing are expected to significantly reduce the incidence of MRSA transmission in the intervention arm, compared to control arms.

Countries

Canada